The NCATS Advisory Council is made up of 18 appointed
members, and the CAN Review Board is comprised of 24 appointed members. They
will both meet on a regular basis to provide guidance, consult, and makes
recommendations to improve the translation of basic science into clinical
application.
The meeting began with an overview of NCATS’ mission and its
role in translational research at NIH, budget details, recent science advances,
and major center milestones. Then NIH Director Francis Collins announced
Christopher P. Austin as the first NCATS director. "There is no way any
one scientific discipline can accomplish what we want to do; we only can be
successful if we do this together," Austin said.
The meeting also included a brief history of CAN’s
establishment, its functions, and its activities. “Collaboration, coordination,
communication, and policy all will play a crucial role in our work to advance
new treatments and cures for patients,” emphasized Freda Lewis-Hall, CAN Review
Board chair.
The Division of Clinical Innovation led presentations
focused on the Clinical and Translational Science Awards (CTSA) program and
participated in a discussion of its goals, achievements, and coordination.
Austin delivered the final presentation of the day, which focused on the Division
of Pre-Clinical Innovation.
In response to a question from a council member about getting
medicines to patients faster, Austin replied: “Through the CTSAs. Combining the
power of these two groups, we can do some magical things."
Relevant Resources on
NCATS and CAN:
No comments:
Post a Comment